@article{fdi:010063886,
  title = {{T}he future role of {CD}4 cell count for monitoring antiretroviral therapy},
  author = {{F}ord, {N}. and {M}eintjes, {G}. and {P}ozniak, {A}. and {B}ygrave, {H}. and {H}ill, {A}. and {P}eter, {T}. and {D}avies, {M}. {A}. and {G}rinsztejn, {B}. and {C}almy, {A}. and {K}umarasamy, {N}. and {P}hanuphak, {P}. and {B}eaudrap, {P}ierre de and {V}itoria, {M}. and {D}oherty, {M}. and {S}tevens, {W}. and {S}iberry, {G}. {K}.},
  editor = {},
  language = {{ENG}},
  abstract = {{F}or more than two decades, {CD}4 cell count measurements have been central to understanding {HIV} disease progression, making important clinical decisions, and monitoring the response to antiretroviral therapy ({ART}). {I}n well resourced settings, the monitoring of patients on {ART} has been supported by routine virological monitoring. {V}iral load monitoring was recommended by {WHO} in 2013 guidelines as the preferred way to monitor people on {ART}, and efforts are underway to scale up access in resource-limited settings. {R}ecent studies suggest that in situations where viral load is available and patients are virologically suppressed, long-term {CD}4 monitoring adds little value and stopping {CD}4 monitoring will have major cost savings. {CD}4 cell counts will continue to play an important part in initial decisions around {ART} initiation and clinical management, particularly for patients presenting late to care, and for treatment monitoring where viral load monitoring is restricted. {H}owever, in settings where both {CD}4 cell counts and viral load testing are routinely available, countries should consider reducing the frequency of {CD}4 cell counts or not doing routine {CD}4 monitoring for patients who are stable on {ART}.},
  keywords = {},
  booktitle = {},
  journal = {{L}ancet {I}nfectious {D}iseases},
  volume = {15},
  numero = {2},
  pages = {241--247},
  ISSN = {1473-3099},
  year = {2015},
  DOI = {10.1016/s1473-3099(14)70896-5},
  URL = {https://www.documentation.ird.fr/hor/fdi:010063886},
}